EXECUTIVE SUMMARY CAR-T cell therapy is a remarkably promising treatment for cancer patients. This emerging treatment is the biggest breakthrough since the introduction of chemotherapy. Already two products (Kymriah and Yescarta) have been approved by the U.S. FDA and European EMA for different cancer indications. What...
Scope of the Report The report titled “Global PD-1 and PD-L1 Inhibitors Market: Size, Trends and Forecasts (2018-2022)”, provides an in depth analysis of the global PD-1 and PD-L1 inhibitors market by value, by cancer, by treatment, by region, etc. The report also provides a detailed analysis of the China PD-1 and PD-L1...
INTRODUCTION Amidst the current initiatives to develop more targeted anti-cancer therapies, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a potent and viable therapeutic intervention to eradicate tumor cells, with minimal side effects. It is based on the principle of harnessing the innate potential of...
Cervical cancer is the fourth most common cancer prevailing in women and the seventh in terms of overall cancer incidences. Cervical cancer diagnostic market in Asian region is growing and expected to cross over USD 1 Billion by 2024. Cervical cancer affects the lower part of the uterus (womb). Cervical cancer generally...
Scope of the Report The report entitled “China Cancer Drug Market: Size, Trends & Forecasts (2018-2022)”, provides analysis of the China cancer drug market, with detailed analysis of market size and growth, and value of the industry. The analysis includes the market by value, by cases and incidence ratio. Moreover,...
This study focuses on China’s Lymphoma Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy....